• Quarterly revenue of $17.1 million, down 12.7% year-over-year
• Net loss of $13.2 million, an improvement from $16.2 million in Q3 2024
• Completed $14.8 million private placement to strengthen balance sheet

AVITA Medical Inc. has reported its financial results for the third quarter of 2025. The company generated total revenue of $17.1 million, down 12.7% compared to the same period in 2024. This decline was driven by lower sales revenue, which fell to $16.9 million from $19.4 million in the prior-year quarter. However, the company's net loss improved to $13.2 million, compared to a net loss of $16.2 million in Q3 2024. During the quarter, AVITA completed a $14.8 million private placement to strengthen its balance sheet. The company also issued 400,000 shares of common stock in connection with a debt amendment. Operating expenses decreased to $23.0 million from $30.2 million in the prior-year period, reflecting the company's ongoing efforts to manage costs.AVITA continues to invest in research and development, with R&D expenses of $3.7 million in the quarter. The company is focused on advancing its product pipeline and expanding its commercial reach to drive future growth.